CA
NZ
UK
AU
IND
US
At the center of the move, President Trump announced plans to restore a blockade on Iranian vessels passing through the Strait of Hormuz, while also imposing a 20% charge on all other cargo using the waterway. Although this specific fee plan was later replaced …
Trump announced he was abandoning plans to impose a 20% reimbursement fee on cargo passing through the Strait of Hormuz under US military protection, a proposal that had itself been a major source of oil market volatility in recent sessions. In place of the …
The combined entity will operate under the leadership of CEO Dr. Andrew Cheng and will prioritize the development of AVR-001, a long-acting cyclic peptide IL-23 receptor antagonist that Avere has licensed from Hansoh Pharma. The ownership structure of the deal reflects Avere's position as …
PMN310 is designed as a selective antibody targeting toxic amyloid-beta oligomers, a specific and increasingly scrutinized form of the amyloid-beta protein implicated in Alzheimer's disease pathology. Unlike some earlier-generation amyloid-targeting therapies that bind more broadly across various forms of amyloid-beta, including plaque deposits, PMN310's …
The royalty financing arrangement with Healthcare Royalty involves Spero monetizing future milestone payments and sales royalties tied to its approved oral antibiotic, Utebzi, which is currently licensed to GSK. This structure allows Spero to convert what would otherwise be a stream of future, uncertain …
The long-term extension data, drawn from 34 patients with up to 15.9 months of drug exposure, showed a 92% reduction in treated bleeding events, a substantial improvement that speaks to sutacimig's potential to meaningfully reduce the bleeding burden faced by patients with this rare …
The scale of this strategic pivot is reflected clearly in the transaction's ownership structure: existing Matinas stockholders will retain only roughly 9% ownership in the reorganized company. A retained stake this modest signals that the substantial majority of the combined company's future equity value …
NanoKnife is a irreversible electroporation-based tissue ablation platform, a technology that uses electrical pulses to destroy targeted tissue without relying on heat or cold-based ablation methods, offering a differentiated approach for treating tumors in anatomically sensitive locations where thermal ablation techniques may pose greater …
For the full fiscal year, pro forma net sales climbed 9.4% to $320.2 million, a growth rate driven predominantly by an 18.4% surge in Med Tech revenue to $150.0 million. This strong Med Tech performance more than offset a comparatively modest 2.5% increase in …
The defining feature of AVR-001 is its engineered pharmacokinetic profile: the molecule has been designed with an approximately 100-hour half-life, enabling once-weekly oral administration. This is a notable achievement in peptide drug design, as cyclic peptides have historically faced challenges achieving the metabolic stability …
Please wait processing your request...